Navigation Links
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Date:6/8/2012

not significant)
  • 1 mg: 57 percent (p<0.05)
  • Placebo: 41 percent
  • ACR50

    • 8 mg: 40 percent (p<0.001)
    • 4 mg: 35 percent (p<0.001)
    • 2 mg: 17 percent (not significant)
    • 1 mg: 31 percent (p<0.05)
    • Placebo: 10 percent

    ACR70

    • 8 mg: 20 percent (p<0.001)
    • 4 mg: 23 percent (p<0.001)
    • 2 mg: 8 percent (not significant)
    • 1 mg: 12 percent (p<0.05)
    • Placebo: 2 percent

    Safety Results

    The most common treatment-emergent adverse event class was infections, with a similar rate observed among patients in the placebo group (12 percent) and patients receiving baricitinib (14 percent). One patient in the placebo group was diagnosed with an opportunistic infection of toxocariasis. No deaths or opportunistic infections occurred in the active treatment groups.

    There were seven serious adverse events reported in six patients (two events in the placebo group, four in the 2 mg group and one in the 8 mg group). Dose-dependent changes in laboratory tests (hemoglobin, neutrophil, serum creatinine, LDL and HDL) were observed, with greater changes being observed in the 8 mg baricitinib group. 

    A copy of the EULAR oral presentation can be accessed at:  Link to Presentation.

    Trial Design and Status

    This Phase IIb trial consists of three parts: Part A, Part B and an open-label extension. Part A was randomized, double-blind and placebo-controlled. Patients randomized to baricitinib received one of four doses administered once daily for 12 weeks.

    In Part B, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once da
    '/>"/>

    SOURCE Eli Lilly and Company; Incyte Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
    2. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
    3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
    4. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
    5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
    6. DiversityInc Names Lilly a Top Company for Diversity
    7. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
    8. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
    9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
    11. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... Sept. 2, 2014  Cyberonics, Inc. (NASDAQ: ... ANTHEM-HF clinical study.  Results of the study presented ... major European cardiology congress and concurrently published by ... Autonomic Regulation Therapy (ART) in patients with moderate ... function is safe, improves the heart,s ability to ...
    (Date:9/2/2014)... Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... agreement to purchase the Interventional business of Bayer ... Scientific to offer physicians and healthcare systems a ... vascular conditions. The addition of the ... supports the Boston Scientific strategy to provide a ...
    (Date:9/2/2014)... 2, 2014  Based on its recent analysis ... Frost & Sullivan recognizes Novian Health, Inc. with ... for Technology Innovation Leadership. Novian Health has greatly ... tumors with its proprietary technology, Novilase ® ... accurate, and easy-to-control ultrasound-guided thermo ablation device that ...
    Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
    ... NEW YORK, Jan. 13, 2011 Although 2010 brought ... healthcare reform repeal.  Investors should likely expect some volatility ... wreak havoc on healthcare reform, either through a repeal ... according to analysts at Standard & Poor,s Equity Research. ...
    ... N.J., Jan. 13, 2011 Quest Diagnostics Incorporated (NYSE: ... information and services, announced today that it will report fourth ... for 2011 on Tuesday, January 25, before the market opens. ... discuss the results beginning at 8:30 a.m. ET on that ...
    Cached Medicine Technology:S&P Equity Research Issues Health Care Sector Predictions for 2011 2S&P Equity Research Issues Health Care Sector Predictions for 2011 3S&P Equity Research Issues Health Care Sector Predictions for 2011 4S&P Equity Research Issues Health Care Sector Predictions for 2011 5S&P Equity Research Issues Health Care Sector Predictions for 2011 6Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results 2
    (Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
    (Date:9/2/2014)... N.J. (PRWEB) September 02, 2014 ... technologies and development solutions for drugs, biologics and ... of its strategic partner, Eli Lilly’s growth, it ... packaging lines at its Philadelphia Clinical Supply Center ... syringe packaging capabilities in its clinical supply facility ...
    (Date:9/2/2014)... York (PRWEB) September 02, 2014 ... of nanotechnology in diagnosing, treating and/or prevention of ... applied for treating cardiovascular, neurological, and oncology diseases. ... of knowledge pertaining to various nanoparticles, their medical ... There still exists considerable scope for research in ...
    (Date:9/2/2014)... JOSE, CA (PRWEB) September 02, 2014 ... computing and collaboration, announces partnership with NTT DoCoMo ... iPad business customers. Splashtop Business Lite is included ... Lite is a remote desktop software that empower users ... anywhere. Splashtop has garnered over 18 million users ...
    (Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will ... tu vida! Get Up! Get Moving!®. This event promotes Hispanic ... wellness for people of all ages and all sizes. The ... be held at Kiest Park Recreation Center, 3080 S. Hampton ... , “Since 2007, we have partnered with National Alliance for ...
    Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
    ... are becoming common everywhere. Only last fortnight it was reported ... 15 ft during a joyride and sustained grievous injuries in ... ,But for a tree branch which checked her ... first aid facilities available, it was reported. ,Now ...
    ... with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage ... to this initial agreement, Delmont Laboratory will supply bulk ... the final packaging in China. ,CBPC will ... to be signed. This product requires a clinical study ...
    ... fill their prescriptions while traveling abroad need to be cautious ... the AAPS National Biotechnology Conference. ,Unlike approved ... internationally. Therefore, consumers should not assume that a branded product ... the same or similar brand name in other counties. ...
    ... seven billion dollar (5.2 billion euro) negligence suit against ... as the US giant demanded the charges be ... early setback when the court rejected a request to ... Babs Kwewumi adjourned the trial to July 20. ...
    ... announces that it has completed its acquisition of ... for approximately $600 million on April 4, 2007. ... owns the patents for Electrochemiluminescence (ECL) technology and ... diagnostics field into new market segments such as ...
    ... called the world's first prototype of an artificial hand with ... up a raw egg. ,Squse, a Kyoto-based ... 400-gramme (14 ounce) hand with five human-sized fingers with artificial ... ,"So far, robots have an image of helping people do ...
    Cached Medicine News:Health News:Girls Feet Severed in Amusement Park Accident 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 3
    ... SINON is a Q-switched ... wavelength of 694 nm. High ... Pulses - This combination of ... pulses in Q-switched mode effectively ...
    ... an in vitro immunoassay intended for the qualititive ... antigen. It is indicated for use as an ... conjunction with cystoscopy or when prescribed for in ... FDA for prescription home use in February 1999. ...
    ... connect an infusion bag ... and then to a ... to conduct urodynamics studies. ... Medical Technologies infusion pumps. ...
    ... Used for cystometry and urethral ... allows for faster filling of the ... readings. Dual lumen catheter construction allows ... cystometry is performed. Triple lumen catheter ...
    Medicine Products: